Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
Anthracyclines have a central role in the treatment of cancer in pediatric patients but confer an increased risk of cardiac dysfunction. Several strategies have been employed to help reduce anthracycline-induced cardiotoxicity, including pretreating the patient with the iron chelator dexrazoxane and infusing the dose of anthracycline over a longer period. Much focus has also been placed on the development of methods that decrease the toxicity of parent compounds, specifically through the use of drug carriers such as liposomes, and on the development of new, potentially less toxic anthracycline derivatives, such as amrubicin and pixantrone. We provide a review of these strategies, focusing on studies in pediatric patients when available, and support the idea that anthracycline therapy can be less cardiotoxic in pediatric patients.
Fulbright
Joy M
JM
Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, USA. jmfulbright@cmh.edu
Huh
Winston
W
Anderson
Pete
P
Chandra
Joya
J
D000293:Adolescent; D000328:Adult; D018943:Anthracyclines / Q000008:administration & dosage / Q000032:analysis / Q000037:antagonists & inhibitors*; D002648:Child; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000633:toxicity; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004337:Drug Carriers / Q000008:administration & dosage / Q000633:toxicity; D054796:Drug Dosage Calculations; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control; D006333:Heart Failure / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011929:Razoxane / Q000008:administration & dosage; D012307:Risk Factors; D016896:Treatment Outcome
D018943:Anthracyclines; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D007502:Iron Chelating Agents; D011929:Razoxane; D004317:Doxorubicin
Clin Pharmacokinet. 2003;42(5):419-36
12739982
Blood. 1991 Apr 15;77(8):1666-74
2015395
J Clin Oncol. 2009 Sep 20;27(27):4522-9
19687336
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD005008
19821337
Leukemia. 2005 Dec;19(12):2130-8
16304572
Anticancer Drug Des. 1990 May;5(2):189-200
2357264
J Cancer Res Clin Oncol. 2006 Jan;132(1):35-40
16205946
J Clin Oncol. 2007 Jul 20;25(21):3179; author reply 3180
17634500
Invest New Drugs. 1997;15(3):219-25
9387044
Pharmacol Rev. 2004 Jun;56(2):185-229
15169927
Ann Oncol. 1993 May;4(5):359-69
8353070
Blood. 2002 Oct 15;100(8):2708-16
12351376
Gan To Kagaku Ryoho. 2001 Nov;28(12):1857-65
11729478
Jpn J Cancer Res. 1998 Oct;89(10):1067-73
9849587
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005006
17054231
J Clin Oncol. 2007 Oct 10;25(29):4689-90; author reply 4690-1
17925567
Cancer. 1973 Aug;32(2):302-14
4353012
Drugs Aging. 1997 Jul;11(1):61-86
9237041
J Clin Oncol. 1985 Jun;3(6):818-26
3859587
Pediatr Blood Cancer. 2005 Jun 15;44(7):584-8
15700251
Clin Cancer Res. 2002 Feb;8(2):413-8
11839657
J Clin Oncol. 2002 Jun 15;20(12):2895-903
12065567
J Clin Oncol. 2002 Mar 15;20(6):1677-82
11896119
Leukemia. 2010 Feb;24(2):320-34
20016537
Am J Med. 1977 Feb;62(2):200-8
835599
J Clin Oncol. 2003 Aug 1;21(15):2940-7
12885813
Cancer. 1993 Nov 15;72(10):3120-30
8221579
Invest New Drugs. 1998;16(2):121-8
9848575
J Clin Oncol. 2001 Mar 1;19(5):1444-54
11230490
Hematol Cell Ther. 1997 Aug;39(4):63-74
9352324
Invest New Drugs. 2007 Aug;25(4):377-83
17351748
Invest New Drugs. 2007 Jun;25(3):253-8
17039404
Jpn J Cancer Res. 1989 Jan;80(1):69-76
2496061
Gan To Kagaku Ryoho. 2001 Nov;28(12):1867-76
11729479
Expert Opin Investig Drugs. 2007 Oct;16(10):1683-91
17922631
Cancer. 2002 Jan 1;94(1):25-36
11815957
J Clin Oncol. 1992 Jul;10(7):1103-11
1607916
Klin Padiatr. 2007 May-Jun;219(3):134-8
17525906
J Pharmacol Exp Ther. 1999 May;289(2):1128-33
10215696
J Clin Oncol. 2008 Mar 1;26(7):1106-11
18309945
Eur J Cancer. 2004 Mar;40(5):643-52
15010064
Pediatr Blood Cancer. 2004 Aug;43(2):152-5
15236282
J Cardiovasc Nurs. 2007 May-Jun;22(3):218-53
17545824
Ann Oncol. 2004 Mar;15(3):440-9
14998846
J Clin Oncol. 2007 Feb 10;25(5):493-500
17290056
J Clin Oncol. 2006 Dec 1;24(34):5448-53
17135647
Drugs. 2005;65(7):1005-24
15892593